Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

The summary for the Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Federal Grant Title:	Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-24-005
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.394, 93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 13th, 2023
Original Application Deadline:	October 13th, 2023
Posted Date:	April 20th, 2023
Creation Date:	April 20th, 2023
Archive Date:	November 18th, 2023
Total Program Funding:
Maximum Federal Grant Award:	$475,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	April 20th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-005.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed); • Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Tria...; • Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Tria...; • Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (...; • Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed); • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translati...; • Integrative Research to Understand the Impact of Sex Differences on the Molecular Determin...; • Limited Competition: Mentored Research Career Development Program Award in Clinical and Tr...; • Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Option...; • Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clini...